KRAS and cancer: In consideration of the universal consensus that PDAC is driven by oncogenic KRAS combined with many cancer genes [35], it can be inferred that these rare neoantigenic mutations may work together with KRAS p.G12V as well as other genetic alterations in cancer-related signaling pathways to influence progression and outcomes of Pt204 in the past 13 years.